A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23.

导出 OA

翻译打印收藏纠错

作者： Yoshinobu,Saito ^[1] ; Dingzi,Yin ^[2] ; Naoto,Kubota ^[3] ; Xiaobo,Wang ^[4] ; Aveline,Filliol ^[4] ; Helen,Remotti ^[5] ; Ajay,Nair ^[4] ; Ladan,Fazlollahi ^[5] ; Yujin,Hoshida ^[3] ; Ira,Tabas ^[6] ; Kirk J,Wangensteen ^[7] ; Robert F,Schwabe ^[8]

作者单位： Department of Medicine, Columbia University, New York, New York. Electronic address: ys3261@cumc.columbia.edu. ^[1] Division of Gastroenterology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Mayo Clinic, Rochester, Minnesota. ^[2] Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. ^[3] Department of Medicine, Columbia University, New York, New York. ^[4] Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York. ^[5] Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York; Institute of Human Nutrition, New York, New York. ^[6] Division of Gastroenterology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Mayo Clinic, Rochester, Minnesota. Electronic address: wangensteen.kirk@mayo.edu. ^[7] Department of Medicine, Columbia University, New York, New York; Institute of Human Nutrition, New York, New York. Electronic address: rfs2102@cumc.columbia.edu. ^[8]

关键词 Anillin CRISPR Combination Therapy Immune Checkpoint Inhibition Kinesin Family Member 23 Liver Cancer Statin Tyrosine Kinase Inhibitor VT104 VT107